|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
Item 8.01
|
Other
Events.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release of Bristol-Myers Squibb Company, dated October 30, 2019.
|
104
|
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
Exhibit
No.
|
|
Description
|
|
|
|
|
Press Release of Bristol-Myers Squibb Company, dated October 30, 2019.
|
|
104
|
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
|
BRISTOL-MYERS SQUIBB COMPANY
|
|
Dated: October 30, 2019
|
By:
|
/s/ Katherine R. Kelly
|
|
Name:
|
Katherine R. Kelly
|
|
Title:
|
Corporate Secretary
|